Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1Carcinoma, Hepatocellular 1

Interventions

enzalutamide 3apalutamide 2relugolix 1pembrolizumab 1nilutamide 1histrelin 1bicalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abiraterone 1Triptorelin Pamoate 1Prednisone 1Oxaliplatin 1Methylprednisolone 1Leuprolide 1Goserelin 1Flutamide 1Fecal Microbiota Transplantation 1Docetaxel 1Androgen Antagonists 1Abiraterone Acetate 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Neoplasm Metastasis × ADI PEG20 × Clear all
NCT00029900 2015-03-25

ADI-PEG in Patients With Metastatic Melanoma

FDA Office of Orphan Products Development

Phase 1 Completed
15 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡